Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 12/20 | 0.48 |
| ▸ | ACE | P12821 | 8/20 | 0.48 |
| ▸ | CPA1 | P15085 | 3/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.42 |
| ▸ | MMEL1 | Q495T6 | 2/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | FCER2 | P06734 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6735727 | 0.94 | MME (0.40) | MMEACEFCER2 | |
| SCHEMBL6735719 | 0.87 | MME (0.49) | MMEACECPA1ACE2MMEL1 | |
| SCHEMBL6736614 | 0.83 | MME (0.39) | MME | |
| SCHEMBL6732077 | 0.83 | CTSS (0.43) | MMEACEMMEL1 | |
| SCHEMBL6897256 | 0.82 | MME (0.38) | MMEACEFCER2 | |
| SCHEMBL7684657 | 0.82 | MME (0.38) | MMEACEFCER2 | |
| SCHEMBL6897114 | 0.82 | MME (0.38) | MMEACEFCER2 | |
| SCHEMBL6731790 | 0.81 | MME (0.50) | MMEACECPA1ACE2MMEL1 | |
| Hydrochloric Acid SCHEMBL6738102 | 0.80 | MME (0.49) | MMEACECPA1ACE2MMEL1 | |
| SCHEMBL6732315 | 0.80 | MAPK1 (0.52) | MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6683200-B2 | N-SUBSTITUTED-N'-SUBSTITUTED UREA DERIVATIVE IS USED AS A TUMOR NECROSIS FACTOR-ALPHA PRODUCTION INHIBITORY AGENT AND A THERAPEUTICAL AGENT FOR AUTOIMMUNE DISEASES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-01-27 | — | — | US | claimed |
| US-20020068763-A1 | N-substituted-N'-substituted urea derivatives and pharmaceutical compositions containing the derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-06-06 | — | — | US | claimed |
| EP-1172358-A1 | N-SUBSTITUTED-N'-SUBSTITUTED UREA DERIVATIVE AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-01-16 | — | — | EP | claimed |
| US-6683200-B2 | N-SUBSTITUTED-N'-SUBSTITUTED UREA DERIVATIVE IS USED AS A TUMOR NECROSIS FACTOR-ALPHA PRODUCTION INHIBITORY AGENT AND A THERAPEUTICAL AGENT FOR AUTOIMMUNE DISEASES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-01-27 | — | — | US | disclosed |
| US-20020068763-A1 | N-substituted-N'-substituted urea derivatives and pharmaceutical compositions containing the derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-06-06 | — | — | US | disclosed |
| EP-1172358-A1 | N-SUBSTITUTED-N'-SUBSTITUTED UREA DERIVATIVE AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068763-A1 | N-substituted-N'-substituted urea derivatives and pharmaceutical compositions containing the derivatives | TNF, NFKBIA, UMPS | MME 922/4885ACE 581/4885CPA1 1163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.